cyrilzakka/clinical-trials huggingface dataset:
Emotional Lived in Patients Suffering From Psychogenic Nonepileptic Seizures : Study by Functional Magnetic Resonance Imaging

Currently, hypothetical models of understanding Psychogenic Non-epileptic Seizures (PNES) involve emotional dysregulation.

The hypothesis of a disorder of emotional experience is mainly based on behavioral data and disturbance of autonomic responses in response to images in emotional content (Mignot et al 2015, in submission; Bakvis et al 2013). Various imaging studies have identified brain structures belonging to the limbic system in particular that seem functionally impaired in this population. These functional connectivity abnormalities are correlated with dissociation scores in PNES patients (Van der Kruijs et al 2012 and 2014).

Investigators propose to specifically study the brain activity of PNES patients during tasks emotional content to identify the mechanisms involved in this emotional dysregulation. This work is essential to understanding the mechanisms and the development of new therapeutic strategies


Eligibility Criteria:
Common Inclusion Criteria:

* Female,
* Right-handed
* Affiliation to the French social security system,
* Informed signing of the study consent.

Specific Inclusion Criteria for PNES group :

* PNES diagnosed by a neurologist specialized in epilepsy, based on clinical symptoms analysis and video-EEG recording,
* Absence of concomitant epilepsy.

Specific Inclusion Criteria for PTSD group : PTSD diagnosed by a psychiatrist, based on clinical symptoms as recorded in DSM5 (Diagnostic and Statistical Manual of Mental Disorders).

Specific Inclusion Criteria for healthy controls : Healthy controls will be paired up with patients on age and level of schooling criteria.

Exclusion Criteria:

common criteria for all groups:

* Neurological history or comorbidity (epilepsy included),
* Current neurological treatment,
* Posology change or introduction of psychoactive treatment dating back to less than a month,
* Psychotic comorbidity (schizophrenia),
* Addiction history apart for smoking,
* History of head trauma,
* Mental retardation,
* Being the subject of articles L.1121-5 to L.1121-8 and L1122-1-2 of the French Code of Public Health (i.e. being a not responsible adult),
* Lack of French language proficiency or inability to understand instructions,
* Uncorrected visual impairment,
* Any contraindication to MRI (pacemaker, ferromagnetic foreign body, claustrophobia, etc.).

Specific exclusion Criteria for PNES group : Diagnosis of PNES challenged or denied by the patient.

Specific exclusion Criteria for PTSD group :

* Diagnosis of PTSD challenged or denied by the patient, current or history of functional neurological symptom disorder,
* History of PNES (conversion disorder).

Specific exclusion Criteria for healthy controls :

* History of PTSD,
* History of PNES (conversion disorder).
Investigation of E-health Literacy Levels of Physiotherapy and Rehabilitation Department Students

This study will be carried out in order to determine the e-health literacy levels of the students of the Department of Physiotherapy and Rehabilitation and to reveal whether the level of their education has an effect on e-health literacy.

It is aimed to contribute to the literature with the objective, evidence-based results to be obtained from the study and to contribute to undergraduate education as a result of the differences between class levels.

Health literacy is generally affected by many factors, from demographic, cultural and psychosocial factors, general literacy level, individual characteristics, experiences related to the disease, and factors related to the healthcare system. It is stated that the evidence supporting the negative effects on the health of individuals is increasing due to the lack of health literacy.

These effects; Low use of preventive healthcare services are shown as delay in seeking health care in the symptomatic period, inability to understand the medical condition of the individual, inability to adhere to medical advice / instructions, insufficient self-care, increase in health care costs and increase in mortality.

In terms of health, health literacy is a stronger determinant than income, employment status, education level, race or ethnic group . The strong place of the concept of health literacy among the main determinants of health appears to be an important factor in the struggle for inequality in health. It is stated that adoption of lifelong learning policies to increase health literacy has important effects .

Since health literacy is directly related to general literacy, studies to be carried out in the field of education can contribute to health literacy and to the improvement of health, thereby reducing health inequalities. It has been determined that the e-health literacy levels of the students studying at Kırıkkale University Faculty of Health Sciences in 2016-2017 differ according to the departments, they are at medium and high levels (average 29.48).

Studies have been suggested to improve the e-health literacy levels of Faculty of Health Sciences students. These recommendations are in line with this study is to determine the students of Physiotherapy and Rehabilitation Department e-health literacy levels in Turkey and will be conducted to determine whether there is effective on the e-health literacy attended class. In case of a difference, secondary goal is to improve the level of health literacy by contributing to undergraduate education.

Eligibility Criteria:
Inclusion Criteria:

* 1st, 2nd, 3rd and 4th year students studying in the Department of Physiotherapy and Rehabilitation of the Faculty of Health Sciences in 2020-2021
* Volunteer to participate in the study

Exclusion Criteria:

* Those who do not study at the Faculty of Health Sciences, Physiotherapy and Rehabilitation Department of universities
* Not volunteering to participate in the study
Short Compared With Standard Duration of Antibiotic Treatment for AECOPD

Chronic obstructive pulmonary disease (COPD) is one of the most common diseases in the world. Acute exacerbation of COPD (AECOPD) refers to an exaggeration of the symptoms of the disease. Currently, the 3 Anthonisen criteria appear to be most satisfactory in defining the AECOPD: The increase in the volume of sputum, the alteration of its appearance which becomes purulent and The increase in dyspnea. Our recent study, showed that administration of levofloxacin is superior to placebo in the treatment of AECOPD; it is accompanied by a substantial reduction in mortality and a significant reduction in the residence time in hospital.The choice of antibiotic to be used in this situation is challenging to the clinician who must choose between traditional antibiotics (cyclins, aminopenicillins, cotrimoxazole...) and new antimicrobial agents. Antibiotic treatment duration was not based on a strong scientific rationale. Yet at the time of the dramatic emergence of bacterial resistance, reducing the selection pressure by reducing the exposure to antibiotic should be a major issue. In addition, the decrease in costs and associated side effects reinforces the interest of short treatments.

Unfortunately, few studies with a satisfactory methodology are available in the literature. In fact, we present the rational and the interest in shortening the durations of antibiotic treatment of AECOPD by levofloxacin in patients admitted to the emergency for exacerbation of COPD and to study the epidemiology of viral and bacterial AECOPD.

This study is a randomized prospective double-blind, accomplished with sealed envelopes ,with two groups :

* Group A: Short treatment duration: 1 tablet Levofloxacin 500mg / day for two days completed by 1 tablet Placebo Levofloxacin 500mg / day for the remaining 5 days.
* Group B: Standard treatment duration (control group): 1 tablet Levofloxacin 500mg / day for 7 days.

The study is conducted by recruiting AECOPD patients to collect their blood samples and sputum samples. These samples will be used for the inflammatory analyses and the study of bacterial and viral serology. The results were seized by the SPSS.20.0 software.

Eligibility Criteria:
Inclusion Criteria:

45 years or older; had a smoking history of at least 10 pack-years; had a clinical diagnosis of mild-to-severe COPD, defined as a postbronchodilator forced expiratory volume in 1 s (FEV1 ) to forced vital capacity ratio of 0·7 or lower and a postbronchodilator FEV1 of at least 30%, according to Global Initiative of Chronic Obstructive Lung Disease (GOLD).

Exclusion Criteria:

Patients were excluded if they presented one of the following conditions: clinical evidence of hemodynamic compromise with need to vasoactive drugs, Glasgow coma scale \&lt;7.20, pneumonia, previous adverse reactions to study drug, antibiotic treatment in the previous days, pregnancy or lactation, severe renal (creatinineclearance 40 mL/min) or hepatic impairment, or lung disease other than COPD that couldaffect the clinical evaluation of the treatments. Patients with active alcohol or drug abuse were also excluded.
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

This is a prospective, multi-center, real-world study designed to evaluate the efficacy and safety of albumin-bound paclitaxel versus paclitaxel or docetaxel in adjuvant treatment of breast cancer.


Eligibility Criteria:
Inclusion Criteria:

1. Female patients aged from 18 to 70 years old;
2. Histologically confirmed as invasive breast cancer;
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
4. Participants achieved complete tumor resection by radical mastectomy, modified radical mastectomy or breast-conserving surgery with negative margins;
5. AC-T adjuvant chemotherapy is planned after breast cancer surgery;
6. Participants with HER-2 negative breast cancer at high risk of recurrence who meet any of the following conditions: 1) HR positive, and ≥4 positive lymph nodes or 1-3 positive lymph nodes with other risk of recurrence \[such as high Ki67 expression (≥20%), T \> 2 cm, age \< 35 years, lymphovascular invasion, grade 3 histology\]; 2) HR negative with positive lymph node or T \> 2 cm;
7. LVEF ≥ 50%;
8. Participants had good compliance with the planned treatment and follow-up, understood the study procedures of this study, and signed informed consent form.

Exclusion Criteria:

1. In the past and present, participants with severe cardiac disease or discomfort , including but not limited: 1) High-risk uncontrolled arrhythmia, atrial tachycardia (heart rate \> 100/min in resting state), significant ventricular arrhythmia (ventricular arrhythmia) or higher atrioventricular block (second-degree type 2 \[Mobitz 2\] atrioventricular block or third-degree atrioventricular block); 2) Angina pectoris requiring anti-angina medication; 3) Clinically significant valvular heart disease; 4) ECG showing transmural myocardial infarction; 5) Uncontrolled hypertension (eg systolic blood pressure \> 180mm Hg or diastolic blood pressure \> 100mmHg); 6) Myocardial infarction; 7) Congestive heart failure;
2. Participants who have received prior any systematic treatment for breast cancer;
3. Participants with bilateral invasive breast cancer;
4. Breast cancer with distant metastasis;
5. Grade 2 or higher Sensory or motor neurotoxicity was present as assessed by CTCAE V5.0;
6. Participants have the following serious illnesses or medical conditions, including but not limited: 1) History of serious neurological or psychiatric disorders, including psychosis, dementia, or epilepsy, that prevent understanding and informed consent; 2) Active uncontrolled infection; 3) Active peptic ulcer, unstable diabetes;
7. Previous or current existence of other malignant tumors other than breast cancer;
8. Severe liver and kidney dysfunction;
9. The presence of any myelodysplastic and other hematopoietic disorders;
10. Participants who are known to be allergic to the active or other components of the study treatment;
11. Participants who are pregnant, breastfeeding, or refuse to use adequate contraception prior to study entry and for the duration of study participation;
12. Participants who were judged by the investigator to be unsuitable for this study.
Development and Validation of a Survival Prediction Model for Esophageal Cancer Patients After Esophagectomy

In this retrospective study, we analyzed data from the Sichuan Cancer Hospital \& Institute Esophageal Cancer Case Management Database (SCH-ECCM Database) from January 2010 to December 2017. Our study focused on examining the clinicopathological characteristics, lymph node removal at each station, and treatment details of patients with esophageal squamous cell carcinoma (ESCC) who underwent esophagectomy. Using this data, we developed a prediction model for OS by considering a combination of clinical characteristics and details of lymphadenectomy variables.

In this retrospective study, we analyzed data from the Sichuan Cancer Hospital \& Institute Esophageal Cancer Case Management Database (SCH-ECCM Database) from January 2010 to December 2017. Our study focused on examining the clinicopathological characteristics, lymph node removal at each station, and treatment details of patients with esophageal squamous cell carcinoma (ESCC) who underwent esophagectomy. Using this data, we developed a prediction model for OS by considering a combination of clinical characteristics and details of lymphadenectomy variables. Additionally, the receiver operating characteristic curve demonstrated an area under the curve greater than 0.7 at 1, 3, and 5 years in both the verification and training groups. Furthermore, Kaplan-Meier (K-M) curves showed that our model effectively distinguished between high- and low-risk groups (p \< 0.01).

Eligibility Criteria:
Inclusion criteria:

* Patients underwent esophagectomy at our hospital.

Exclusion criteria:

* pathology confirmed a non-squamous cell carcinoma,
* the tumor was located outside of the thoracic region,
* R1/R2 resection was performed indicating incomplete tumor removal,
* evidence of distant tumor metastasis was observed, or
* they underwent preoperative neoadjuvant therapy
Improving Patient Understanding of the Surgical Hospital Experience: Use of YouTube Video Playlist

This prospective randomized pilot clinical trial studied the effect on preoperative anxiety of watching a series of YouTube videos designed to create a virtual hospital experience for patients undergoing primary total hip and knee arthroplasty as compared to routine preoperative education.

Hypothesis: Preoperative anxiety related to hip and knee replacement surgeries can be reduced by patient exposure to a virtual hospital inpatient experience delivered by a series of YouTube videos.

As high patient anxiety prior to surgery has been linked to more severe and persistent pain after joint replacement surgery, the Orthopedic Surgery Department at Mayo Clinic in Florida created a playlist of 16 YouTube videos aimed at creating a virtual hospital experience for primary total hip and knee joint replacement patients. A pilot study was then performed to evaluate the potential impact of viewing this playlist on preoperative anxiety.

Methods: Each patient completed a Generalized Anxiety Disorder Score (GAD) assessment at the time of the routine preoperative clinic visit and were then randomized based on their gender, type of surgery, and initial GAD score to either the control group of standard education (education at face-to-face clinical visits as well as printed educational materials) or the treatment group of standard education plus access to the YouTube playlist. On the morning of the patient's surgery the same survey was repeated.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing primary total hip or total knee arthroplasty at Mayo Clinic in Florida
* Patients must be able to give consent to the study
* Patients must agree to watch the videos prior to scheduled surgery
* Patients must agree to complete the questionnaire in the office and again prior to surgery on the day of surgery

Exclusion Criteria:

* No internet access at home
* Visual or auditory conditions which limit a patient's ability to view the You Tube videos at home
Deep Lamellar Endothelial Keratoplasty: Small Incision Technique

The research objectives of this study are to determine if small incision Deep Lamellar Endothelial Keratoplasty (DLEK) is able to further reduce the degree of corneal astigmatism and shorten the time course of corneal topography stabilization compared to standard full thickness corneal transplant (PKP) surgery.

Split thickness lamellar corneal transplants have been performed for many years to replace the front part of the cornea and have been highly successful. What is different about this study is that the surgical procedure involves replacement of the back layers of the cornea rather than the front layers of the cornea. This replacement is done through a small pocket incision to avoid changes in the front surface of the cornea. By leaving the front surface in the cornea without sutures or incisions there is felt to be an advantage in healing and recovery time for the patient. In addition, this particular study will use a pocket incision that is even shorter and smaller in length than the one used in previous DLEK surgeries to try to make healing time even faster and more predictable. This procedure has been successfully performed on patients in the Netherlands for over five years. The procedure has also been successfully performed by doctors in the United States. Subjects participating in this study will be among the first patients to undergo this procedure in the The University of Texas Southwestern Medical Center at Dallas.

Eligibility Criteria:
Inclusion Criteria: Subjects enrolled in this study will have endothelial dysfunction to a level generally accepted as requiring standard PKP for treatment. Subjects will be offered the alternative surgery of this protocol. All subjects will be between the ages of 21 and 95. Males and females are eligible.

-

Exclusion Criteria: Central corneal scars, presence of a filtering bleb and uncontrolled glaucoma.

-
Professional Quality of Life in German Psychologists

The purpose of this study is to assess professional quality of life in German psychologists working with patients with mental disorders.

The purpose of this study is to assess professional quality of life, which includes compassion satisfaction, burnout and secondary traumatization in clinical psychologists, working with patients with mental disorders, in Germany.

Eligibility Criteria:
Inclusion Criteria:

* Clinical psychologist
* Currently working with patients with mental disorders
* At least 18 years old
* Sufficient German skills for answering the questionnaire

Exclusion Criteria:

None
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy

This study aims at evaluating efficacy and safety of berberine-containing quadruple therapy(berberine, lansoprazole, bismuth and amoxicillin) versus clarithromycin-containing quadruple therapy (clarithromycin,lansoprazole, bismuth and amoxicillin) in H. pylori eradication. It is hypothesized that berberine-containing quadruple therapy is non-inferior to clarithromycin-containing quadruple therapy. Patients with confirmed H. pylori positive status will be randomized to one of the treatments described above. At week 2 and 6 follow-up visits, a urea breath test(UBT) will be performed to confirm eradication.

The study will include three phases: screening, treatment and follow-up. Screening: this phase will last a maximum of 28 days and subjects eligibility will be evaluated after informed consent signature. Endoscopy and Urea Breath test will be performed in addition to the baseline routine evaluations.

Treatment: Subjects are randomly assigned to treatment and will be treated for 14 days. A randomization visit will take place on Day 0 and an end-of-treatment visit will take place between day 12 and 14.

Follow-up: includes two visits. approximately 14 days of treatment and 28 days after the end of treatment. Eradication of H. Pylori will be confirmed through urea breath test(UBT).

Eligibility Criteria:
Inclusion Criteria:

1. Age between 18\~70,both gender.
2. Patients with upper gastrointestinal symptoms and with documented H.pylori infection.
3. Patients are willing to receive eradication treatment.
4. Women are eligible if they are not pregnant or nursing, and if they are of childbearing potential they are required to use medically acceptable contraception for the duration of the study and 30 days thereafter.

Exclusion Criteria:

1. Patients are excluded if they have previously used antibiotics to eradicate adequately recorded infection with H. pylori.
2. Contraindications to study drugs.
3. Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.
4. Constant use of anti-ulcer drugs ( including taking proton-pump. inhibitors(PPI) within 2 weeks before the \[13C\] urea breath test), antibiotics or bismuth complexes (more than 3 times /1 month before screening)
5. Pregnant or lactating women.
6. Underwent upper gastrointestinal Surgery.
7. Patients with Barrett esophageal or highly atypical hyperplasia, have symptom of dysphagia.
8. Evidence of bleeding or iron efficiency anemia.
9. A history of malignancy.
10. Drug or alcohol abuse history in the past 1 year.
11. Systemic use of corticosteroids, non steroidal anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors (except the use of aspirin for less than 100 mg/d).
12. Enrolled in other clinical trials in the past 3 months.
Trial Comparing 19 and 25-gauge EUS-FNA Needles

This study compares the 19G and 25G needles for procuring tissue samples from the pancreas during Endoscopic Ultrasound (EUS) procedures.

The study compares the median number of passes to establish a definitive diagnosis using the 19G or 25G needles. Also, the ability of both needles to procure a histological core tissue is assessed.

Eligibility Criteria:
INCLUSION CRITERIA:

(1) Patients with solid pancreatic mass lesions.

EXCLUSION CRITERIA:

1. Age \< 19 years
2. Unable to safely undergo EUS for any reason
3. Coagulopathy (INR \> 1.6, Prothrombin Time \> 18secs, Thrombocytopenia \< 80,000 cells/ml)
4. Unable to consent
5. Non-English speaking patients